Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China.
Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China.
Int Immunopharmacol. 2023 Nov;124(Pt B):110987. doi: 10.1016/j.intimp.2023.110987. Epub 2023 Oct 6.
To develop a new scoring system based on platelet-to-lymphocyte ratio (PLR) and CA199 to predict the prognosis of gastric cancer.
PLR-CA199 was identified in a retrospective study that was conducted in a training cohort of 990 gastric cancer patients who underwent curable resection from 2012 to 2014 and validated in a validation cohort of 625 patients between 2015 and 2016.
In the training cohort, PLR-CA199 was related to gender (P = 0.041), age (P = 0.014), tumor location (P = 0.015), tumor size (P < 0.001), Bormann type (P < 0.001), vascular invasion (P < 0.001), perineural invasion (P < 0.001), and TNM staging (P < 0.001). In the validation cohort, PLR-CA199 was related to tumor size (P < 0.001), Bormann type (P = 0.007), vascular invasion (P < 0.001), perineural invasion (P < 0.001), and TNM staging (P < 0.001). Survival analysis showed that in the training cohort the mean disease-free survival (DFS) was 70.699 months for patients PLR-CA199 = 0, 51.223 months for patients PLR-CA199 = 1, and 32.152 months for patients PLR-CA199 = 2 (P < 0.001). The correlation between PLR-CA199 and DFS was further confirmed in the validation cohort (50.640 vs. 41.842 vs. 22.382, P < 0.001). Survival analysis showed that the mean disease special survival (DSS) was 76.668 months for patients PLR-CA199 = 0, 61.218 months for patients PLR-CA199 = 1, and 44.665 months for patients PLR-CA199 = 2 in the training cohort (P < 0.001). The correlation between PLR-CA199 and DSS was further confirmed in the validation cohort (53.858 vs. 46.385 vs. 44.665, P < 0.001). Furthermore, univariate and multivariate analyses showed that PLR-CA199 was an independent prognostic factor for DFS and DSS.
Preoperative PLR-CA199 may be a useful prognostic indicator, and is a promising tool for predicting the prognosis for gastric cancer.
基于血小板与淋巴细胞比值(PLR)和 CA199 建立新的评分系统,以预测胃癌的预后。
回顾性分析了 990 例 2012 年至 2014 年接受根治性切除术的胃癌患者的训练队列,确定了 PLR-CA199,并用 2015 年至 2016 年的 625 例患者的验证队列进行验证。
在训练队列中,PLR-CA199 与性别(P=0.041)、年龄(P=0.014)、肿瘤位置(P=0.015)、肿瘤大小(P<0.001)、Bormann 分型(P<0.001)、血管侵犯(P<0.001)、神经侵犯(P<0.001)和 TNM 分期(P<0.001)有关。在验证队列中,PLR-CA199 与肿瘤大小(P<0.001)、Bormann 分型(P=0.007)、血管侵犯(P<0.001)、神经侵犯(P<0.001)和 TNM 分期(P<0.001)有关。生存分析显示,在训练队列中,PLR-CA199=0、PLR-CA199=1 和 PLR-CA199=2 的患者的中位无病生存(DFS)分别为 70.699 个月、51.223 个月和 32.152 个月(P<0.001)。PLR-CA199 与 DFS 的相关性在验证队列中得到进一步证实(50.640 比 41.842 比 22.382,P<0.001)。生存分析显示,在训练队列中,PLR-CA199=0、PLR-CA199=1 和 PLR-CA199=2 的患者的中位疾病特异性生存(DSS)分别为 76.668 个月、61.218 个月和 44.665 个月(P<0.001)。PLR-CA199 与 DSS 的相关性在验证队列中也得到了进一步证实(53.858 比 46.385 比 44.665,P<0.001)。此外,单因素和多因素分析表明,PLR-CA199 是 DFS 和 DSS 的独立预后因素。
术前 PLR-CA199 可能是一种有用的预后指标,是预测胃癌预后的有前途的工具。